Validating Complex Biomarker Panels & Innovative Diagnostic Platforms Across Europe For Scalable Precision Medicine Approvals, Adoption & Market Access. With IVDR performance study guidance now in force, German reimbursement reforms underway, and NHS England advancing liquid biopsy rollouts, Europe is entering a new era of precision medicine. As novel and digital diagnostics accelerate, the question is no longer whether they enable fit-for-purpose biomarker strategies, but how quickly clinical, regulatory, and commercial systems can keep pace. Amid this momentum, the 16th World Clinical Biomarkers & Companion Diagnostics Summit Europe returns as the region’s longest-standing precision medicine forum, bringing together 300+ senior leaders across biopharma, diagnostics, regulation, reimbursement, and healthcare to define biomarker strategies and ensure day-one drug-diagnostic market readiness.

Empowering Timely & Affordable Drug-Diagnostic Access Across APAC Through Harmonized Trial Management, Policy Shaping, & Testing Adoption. With rising demand for targeted therapies and testing access, the Asia-Pacific region is becoming a rising player in the co-development and commercialization of drug-diagnostic strategies. In under a year, Singapore has accelerated public-private partnerships to scale genomic testing, China has expanded national reimbursement for liquid biopsies, and Japan has refined its regulatory framework for companion diagnostic approvals. Returning for its second year, the World Liquid Biopsy & Companion Diagnostics Summit APAC will unite 100+ leaders across biopharma, diagnostics, regulation, and healthcare to drive the co-development and commercialization of affordable, scalable, and timely testing solutions.

We are excited to announce that the most comprehensive, industry-dedicated event for the spatial biology community will return to Boston this October!

This year’s *free to attend event returns with 15+ case studies showcasing never-before-seen data from AbbVie, Pfizer, Genentech, Takeda, and more. Covering critical challenges, from limited throughput and integrating omics to bridging digital histopathology with spatial data, you will be equipped with the toolkit to scale spatial biology for your pipeline, catalyzing deeper insights across the drug development continuum.

If you are a Vendor or Solution Provider, use the 10% discount code to join the spatial biology community: MEDXPRT10

Fuelled by industry excitement like the world-first approval of a digital pathology CDx, the biomarker and diagnostics field continues to surge.

Uniting 600+ precision medicine experts this September, the 15th World Clinical Biomarkers & Companion Diagnostics Summit returns with a refreshed 4-day, 3-track, 50+-speaker program, ready to facilitate connection-making and knowledge-sharing to bring affordable precision healthcare to patients with unmet need.

• 600+ attendees from biopharma and diagnostic providers
• 50+ precision medicine experts on the speaker faculty
• 66+ data-driven presentations spanning the end-to-end of drug-diagnostic co-development

The 4th Liquid Biopsy for Precision Oncology East Coast Summit returns to Boston with a refreshed agenda, and a renewed mission: to accelerate access to more sensitive, less invasive testing by addressing the most pressing challenges across the entire patient care continuum.

Advance precision IBD therapies with AI, biomarkers & expert insights in Boston this May. Join leading minds in IBD at the 3 rd Precision Medicine in Inflammatory Bowel Disease Summit, taking place this May in Boston. As groundbreaking data and promising clinical advances shape a new era in IBD treatment, this meeting brings together precision medicine and IBD experts from biopharma, diagnostics, and academia.

Sharing Case Studies in Navigating Complex Regulatory & Operational Hurdles to Operate Successful Early Access, Expanded Access, Managed Access & Post-Trial Access Programs. Expanded Access Programs (EAPs) are increasingly recognized as an ethical imperative in modern healthcare. More companies are opening EAPs to provide critical therapies to patients who would otherwise lack access. However, challenges persist, especially when navigating the complex regulatory landscape of global programs. From country-specific regulations to post-trial access, managing global supply chains, importation, licensing, and labeling standards remains a critical focus for ensuring patients worldwide receive the treatments they need.

The 7th CKD Drug Development Summit returns in 2025 as the definitive forum for connecting industry leaders, KOLs, researchers, and regulators. Addressing the most pressing challenges across renal research and development, this event serves as the unrivaled platform to share breakthroughs, inspire collaboration, and advance strategies for improving clinical outcomes in renal care all to bring better drugs to patients faster.

Optimizing Sustained Release Drug Formulation, Showcasing Advancements in Suprachoroidal Delivery, and Assessing Clinical Benefits to Demonstrate Safe, Efficacious and Long-Lasting Delivery to the Eye. The importance of matching the right drug delivery route to the right ophthalmic disease is more pressing than ever. The 3rd Ophthalmic Drug Delivery Summit is the premier gathering for the industry to discuss and explore innovations and future directions for ophthalmic device and formulation development. Delve into the latest in-depth analysis of intravitreal, subretinal, suprachoroidal and topical delivery and explore advancements in ophthalmic pharmacology.

Integrating Expertise from Software Development, Quality Assurance, Regulatory Affairs, & Product Teams to Drive Innovation in Alignment with Global Regulatory Guidelines, AI & ML Enabled Software, Cybersecurity, & Agile Methodologies. The European market is capturing 30% of the global medical device field driven by rapid advances in innovative software, AI, and ML. But as medical device developers are met with tedious submission processes, ever-changing software patches, and red tape at every turn, it has never been more important to break out of cross-functional silos and stay two steps ahead of compliance guidelines.